Analyst Says News of FDA Panel for Salix's Relistor Could Provide 'Another Meaningful Catalyst'

With Salix Pharmaceutical's (NASDAQ: SLXP ) Relistor scheduled for an FDA panel within the next three to four months, Cantor Fitzgerald's Irina Rivkind sees “another meaningful catalyst” for investors in Salix. The analyst especially liked the prospect for the panel meeting ahead of expected retreatment due from Xifaxan IBS-D